Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems

The incidence of<b> </b>neglected diseases in tropical countries, such as Leishmaniasis and Chagas’s disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health ca...

Full description

Bibliographic Details
Main Authors:	Eliana B. Souto, João Dias-Ferreira, Sara A. Craveiro, Patrícia Severino, Elena Sanchez-Lopez, Maria L. Garcia, Amélia M. Silva, Selma B. Souto, Sheefali Mahant
Format:	Article
Language:	English
Published:	MDPI AG 2019-08-01
Series:	Pathogens
Subjects:	Neglected diseases drug delivery systems antiprotozoal agents Chagas’s disease leishmaniasis
Online Access:	https://www.mdpi.com/2076-0817/8/3/119

id	doaj-7a531680f9734232a6365d7693f1b146
record_format	Article
spelling	doaj-7a531680f9734232a6365d7693f1b1462020-11-24T22:15:26ZengMDPI AGPathogens2076-08172019-08-018311910.3390/pathogens8030119pathogens8030119Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological SystemsEliana B. Souto0João Dias-Ferreira1Sara A. Craveiro2Patrícia Severino3Elena Sanchez-Lopez4Maria L. Garcia5Amélia M. Silva6Selma B. Souto7Sheefali Mahant8Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, PortugalDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, PortugalFaculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 296, Paranhos, 4200-150 Porto, PortugalLaboratory of Nanotechnology and Nanomedicine (LNMED), Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49010-390, BrazilDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, SpainDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, SpainDepartamento de Biologia e Ambiente, Universidade de Trás-os-Montes e Alto Douro (UTAD), P.O. Box 1013; 5001-801 Vila Real, PortugalDepartment of Endocrinology of Braga Hospital, Sete Fontes, 4710-243 São Victor, Braga, PortugalDepartment of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana 124001, IndiaThe incidence of<b> </b>neglected diseases in tropical countries, such as Leishmaniasis and Chagas’s disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health care systems. Both Leishmaniasis and Chagas’s disease are caused by different protozoa and develop diverse symptoms, which depend on the specific species infecting man. Currently available drugs to treat these disorders have limited therapeutic outcomes, frequently due to microorganisms’ drug resistance. In recent years, significant efforts have been made towards the development of innovative drug delivery systems aiming to improve bioavailability and pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of Leishmaniasis and Chagas’s disease, the currently available pharmacological therapies and the new drug delivery systems for conventional drugs.https://www.mdpi.com/2076-0817/8/3/119Neglected diseasesdrug delivery systemsantiprotozoal agentsChagas’s diseaseleishmaniasis
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Eliana B. Souto João Dias-Ferreira Sara A. Craveiro Patrícia Severino Elena Sanchez-Lopez Maria L. Garcia Amélia M. Silva Selma B. Souto Sheefali Mahant
spellingShingle	Eliana B. Souto João Dias-Ferreira Sara A. Craveiro Patrícia Severino Elena Sanchez-Lopez Maria L. Garcia Amélia M. Silva Selma B. Souto Sheefali Mahant Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems Pathogens Neglected diseases drug delivery systems antiprotozoal agents Chagas’s disease leishmaniasis
author_facet	Eliana B. Souto João Dias-Ferreira Sara A. Craveiro Patrícia Severino Elena Sanchez-Lopez Maria L. Garcia Amélia M. Silva Selma B. Souto Sheefali Mahant
author_sort	Eliana B. Souto
title	Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
title_short	Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
title_full	Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
title_fullStr	Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
title_full_unstemmed	Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
title_sort	therapeutic interventions for countering leishmaniasis and chagas’s disease: from traditional sources to nanotechnological systems
publisher	MDPI AG
series	Pathogens
issn	2076-0817
publishDate	2019-08-01
description	The incidence of<b> </b>neglected diseases in tropical countries, such as Leishmaniasis and Chagas’s disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health care systems. Both Leishmaniasis and Chagas’s disease are caused by different protozoa and develop diverse symptoms, which depend on the specific species infecting man. Currently available drugs to treat these disorders have limited therapeutic outcomes, frequently due to microorganisms’ drug resistance. In recent years, significant efforts have been made towards the development of innovative drug delivery systems aiming to improve bioavailability and pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of Leishmaniasis and Chagas’s disease, the currently available pharmacological therapies and the new drug delivery systems for conventional drugs.
topic	Neglected diseases drug delivery systems antiprotozoal agents Chagas’s disease leishmaniasis
url	https://www.mdpi.com/2076-0817/8/3/119
work_keys_str_mv	AT elianabsouto therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT joaodiasferreira therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT saraacraveiro therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT patriciaseverino therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT elenasanchezlopez therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT marialgarcia therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT ameliamsilva therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT selmabsouto therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems AT sheefalimahant therapeuticinterventionsforcounteringleishmaniasisandchagassdiseasefromtraditionalsourcestonanotechnologicalsystems
_version_	1725794323148046336

Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems

Similar Items